Content
Prescription weight loss that puts you first
Ozempic® (semaglutide) and other GLP-1 medications are increasingly popular for their effectiveness in supporting weight loss goals.
But some folks on the internet have started asking whether certain weight loss medications could trigger depression or other mental health issues.
The Food and Drug Administration (FDA) has been reviewing reports about suicidal thoughts and behaviors in people taking GLP-1s. These reports have been submitted to the FDA’s Adverse Event Reporting System (FAERS).
It makes sense that an uptick in people using something would result in an uptick in claims of adverse effects, but it's also important to understand that anyone can submit one of these claims — they are not regulated and can be duplicated.
While the FDA has reported no evidence of a causal link between semaglutide and depression, that doesn’t mean it’s not happening at all. At the very least, the mental health side effects associated with weight loss medications are worth discussing.
Content
In its 2024 report, the FDA says it has been evaluating reports of suicidal thoughts and actions among GLP-1 users and has found no evidence that GLP-1 agonists cause suicidal thoughts or actions.
It’s important to note that reports submitted to FAERS can be posted by anyone. They are not individually verified and there is potential for duplication. Still, the reports of mental health effects associated with GLP-1 drugs are an issue the FDA will continue to monitor.
The FDA points to the difficulty in narrowing in on the cause of suicidal thoughts and activities. The 2024 report says a review of clinical trials found some evidence of these thoughts and behaviors in people taking GLP-1 agonists but at the same rates as people taking placebos.
Interestingly, some research suggests that people using GLP-1 agonists for diabetes management experience a reduced risk of anxiety and depression. All of this information confirms one thing: There needs to be further exploration into how these drugs can impact individuals’s mental health.
Ozempic is a glucagon-like peptide-1 receptor agonist (GLP-1) medication. Other types of GLP-1s include Saxenda® (liraglutide), which garnered reports of suicidal thoughts during its clinical trials.
Because of these reports, Saxenda and Wegovy® (semaglutide) — another GLP-1 — both have warnings regarding mood changes on their labels. The FDA advises healthcare practitioners to look out for signs of mental health concerns in patients taking Wegovy.
Ozempic, on the other hand, bears no such warnings.
Still, the association cannot be definitively ruled out, and therefore the FDA says it’s continuing to look into the issue. If you are experiencing any adverse events from your medication, reach out to a healthcare provider or trusted support organization.
Ozempic works by mimicking the action of the naturally occurring hormone GLP-1 (glucagon-like peptide-1). The hormone is released in response to food intake, boosting insulin secretion in response to rising blood sugar levels.
For this reason, Ozempic is FDA-approved to help lower blood sugar levels in adults with type 2 diabetes.
Ozempic also impacts the brain, acting on GLP-1 receptors located in areas that are involved in hunger and reward pathways. This interaction promotes feelings of satiety and reduces appetite, leading to reduced food intake.
Furthermore, Ozempic slows gastric emptying, which means food stays in your stomach longer and promotes prolonged feelings of fullness after eating.
For these reasons, some healthcare providers might prescribe Ozempic off-label for weight management. This means using Ozempic for a reason other than its FDA-approved indication for type 2 diabetes.
So, could semaglutide cause depression? We examined the possible reasons next.
What’s behind these anecdotal reports of people feeling depressed when taking Ozempic? Can weight loss injections cause depression?
While research is ongoing to determine whether there is any connection between GLP-1 agonists and depression, no link has been identified yet. Until more data is collected, there are a few potential explanations.
First, Ozempic is used for the treatment of type 2 diabetes and, off-label, obesity, which means many people who use it are naturally at a higher risk for depression to begin with.
It’s possible that those prescribed Ozempic have underlying conditions that make them more likely to have depression symptoms. There may also be a link between obesity and changes in the gut microbiome (the community of bacteria in your gut) that increases one’s susceptibility to mood changes.
Furthermore, depression is not an uncommon mental health diagnosis. Around ten percent of people in the general population have had a major depressive episode.
It could be coincidental when underlying depression surfaces during the time someone is taking Ozempic, but, again, more research will help clarify this issue.
Ozempic has several potential side effects, but depression and suicidality are not mentioned on the drug packaging.
Some of the more commonly reported side effects of Ozempic are gastrointestinal, including:
Nausea
Vomiting
Constipation
Diarrhea
More serious side effects can include kidney failure, vision problems, gallbladder issues, thyroid tumors, and inflammation of the pancreas.
Research shows no link between using Ozempic or other GLP-1 drugs and developing depression.
That doesn’t mean an association doesn’t exist; we just need more research to determine what’s going on.
In the meantime, here are some potential indications of depression that would warrant speaking with your healthcare provider:
Ongoing feelings of sadness or emptiness
Loss of interest in things you used to enjoy
Significant unintentional weight gain or loss
Disturbances in sleep
Fatigue or loss of energy nearly every day
Feelings of worthlessness or guilt
Difficulty concentrating
Noticeable restlessness or feeling mentally or physically slower than normal
Irritability
Trouble making decisions, concentrating, or remembering things
Crying spells without a specific trigger
Recurrent thoughts of death or suicide attempts
Note that having one or more of these symptoms doesn’t automatically mean you have depression. It’s when these symptoms start to pile up, last longer than a few weeks, and start interfering with your everyday life that you should be concerned.
Still, it’s always a good idea to seek professional help if you're concerned about how you're feeling, whether it’s related to Ozempic and anxiety, mood changes, or depression.
Can semaglutide cause depression? According to the FDA, there is currently no definitive research to show a direct causal link between Ozempic and depression.
Still, that doesn't mean one doesn’t exist — nor does it discredit what many people using it are facing.
If you or someone you know is experiencing depression, suicidal ideation, thoughts of self-harm, or other mental health obstacles affecting quality of life, help is available:
You can reach the National Suicide Prevention Lifeline at 988, or text HOME to 741-741 for the Crisis Text Line.
Other mental health services are also available. One option is to call the National Helpline of the Substance Abuse and Mental Health Services Administration (SAMHSA) at 1-800-662-HELP (4357).
Your mental health matters. If you’re struggling while taking Ozempic, you’re not alone. Let’s get things back on track so you can focus on what else is important to you.
Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!
Dr. Mike Bohl is a licensed physician and the Director of Medical Content & Authority at Hims & Hers. Prior to joining Hims & Hers, Dr. Bohl worked in digital health at Ro, focusing on patient education, and as the Director of Scientific & Medical Content at a stealth biotech startup, working on pharmaceutical drug development. He has also worked in medical journalism for The Dr. Oz Show (receiving recognition for contributions from the National Academy of Television Arts and Sciences when the show won Outstanding Informative Talk Show at the 2016–2017 Daytime Emmy® Awards) and at Sharecare, and he is a Medical Expert Board Member at Eat This, Not That!.
Dr. Bohl obtained his Bachelor of Arts and Doctor of Medicine from Brown University, his Master of Business Administration and Master of Science in Healthcare Leadership from Cornell University, his Master of Public Health from Columbia University, and his Master of Liberal Arts in Extension Studies—Journalism from Harvard University. Dr. Bohl trained in internal medicine with a focus on community health at NYU Langone Health.
Dr. Bohl is Certified in Public Health by the National Board of Public Health Examiners, Medical Writer Certified by the American Medical Writers Association, a certified Editor in the Life Sciences by the Board of Editors in the Life Sciences, a Certified Personal Trainer and Certified Nutrition Coach by the National Academy of Sports Medicine, and a Board Certified Medical Affairs Specialist by the Accreditation Council for Medical Affairs. He has graduate certificates in Digital Storytelling and Marketing Management & Digital Strategy from Harvard Extension School and certificates in Business Law and Corporate Governance from Cornell Law School.
In addition to his written work, Dr. Bohl has experience creating medical segments for radio and producing patient education videos. He has also spent time conducting orthopaedic and biomaterial research at Case Western Reserve University and University Hospitals of Cleveland and practicing clinically as a general practitioner on international medical aid projects with Medical Ministry International.
Dr. Bohl lives in Manhattan and enjoys biking, resistance training, sailing, scuba diving, skiing, tennis, and traveling. You can find Dr. Bohl on LinkedIn for more information.
Younesi, M., Knapik, D. M., Cumsky, J., Donmez, B. O., He, P., Islam, A., Learn, G., McClellan, P., Bohl, M., Gillespie, R. J., & Akkus, O. (2017). Effects of PDGF-BB delivery from heparinized collagen sutures on the healing of lacerated chicken flexor tendon in vivo. Acta biomaterialia, 63, 200–209. https://www.sciencedirect.com/science/article/abs/pii/S1742706117305652?via%3Dihub
Gebhart, J. J., Weinberg, D. S., Bohl, M. S., & Liu, R. W. (2016). Relationship between pelvic incidence and osteoarthritis of the hip. Bone & joint research, 5(2), 66–72. https://boneandjoint.org.uk/Article/10.1302/2046-3758.52.2000552
Gebhart, J. J., Bohl, M. S., Weinberg, D. S., Cooperman, D. R., & Liu, R. W. (2015). Pelvic Incidence and Acetabular Version in Slipped Capital Femoral Epiphysis. Journal of pediatric orthopedics, 35(6), 565–570. https://journals.lww.com/pedorthopaedics/abstract/2015/09000/pelvic_incidence_and_acetabular_version_in_slipped.5.aspx
Islam, A., Bohl, M. S., Tsai, A. G., Younesi, M., Gillespie, R., & Akkus, O. (2015). Biomechanical evaluation of a novel suturing scheme for grafting load-bearing collagen scaffolds for rotator cuff repair. Clinical biomechanics (Bristol, Avon), 30(7), 669–675. https://www.clinbiomech.com/article/S0268-0033(15)00143-6/fulltext